Table 2.
Clinical outcomes of the 113 patients.
| n | % | |
|---|---|---|
| Tumor response | ||
| CR | 20 | 17.7 |
| PR | 74 | 65.5 |
| SD | 13 | 11.5 |
| PD | 6 | 5.3 |
| Local control rate | ||
| 1-year | - | 57.4% |
| 2-year | - | 41.8% |
| 3-year | - | 29.3% |
| 5-year | - | 15.2% |
| Time to progression | Median 15 months | - |
| Overall survival | Median 20 months | - |
| Overall survival rate | ||
| 1-year | - | 63.6% |
| 2-year | - | 44.6% |
| 3-year | - | 29.9% |
| 5-year | - | 21.7% |
| Complications | ||
| Skin | ||
| Grade I, II | 18 | 15.9 |
| Grade ≥III | 8 | 7.0 |
| Mucosal | ||
| Grade I, II | 14 | 12.4 |
| Grade ≥III | 3 | 2.7 |
| Others | ||
| Grade I, II | 0 | - |
| Grade ≥III | 0 | - |
CR, complete response; PR, partial response; PD, progression disease; SD, stable disease.